Investor Presentaiton slide image

Investor Presentaiton

US Business - Significant Ramp-up in Sales SUN PHARMA 10 year CAGR 47% 35 23 14 5 15 3 4 11 FY05 FY06 FY07 FY05 - FY14 numbers exclude Ranbaxy financials * FY15 numbers include the impact of Ranbaxy merger © Sun Pharmaceutical Industries Limited. All Rights Reserved. Sales in Rs billion! 98 137 FY98 Key Milestones in US FY98-FY10 • FY08 onwards FY10 • • Entry in US through Caraco acquisition Ramp-up in US business Launched many complex generics & few FTFs • Acquired Taro Pharma – Entry into dermatology market =2 62 • FY13 Acquired DUSA - Entry in FY13 • . FY14 FY15 • branded specialty market Acquired URL's generic business Acquired Pharmalucence -access to sterile injectable capacity Acquired InSite Vision - Strengthen ophthalmic portfolio FY13 FY14 FY15* 18
View entire presentation